Nutritional Lipidomics in Alzheimer's Disease.
Study Goal
The researchers aimed to analyze altered lipid metabolites, including ceramides, and the impact of diet in the progression of Alzheimer's disease.
Results Summary
The abstract suggests that lipidomic data, including ceramides, may serve as a diagnostic tool for early Alzheimer's disease and identify novel therapeutic targets, but specific efficacy results for ceramides are not detailed.
Population
General focus on Alzheimer's disease, but no specific population details provided.
Effective Dosage
Not available
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
lipidomic data | neutral | Alzheimer's disease | - | - | can be used as a diagnosing tool | #1 |
altered lipid metabolites | neutral | progress of Alzheimer's disease | - | - | are analyzed | #2 |
diet | neutral | progress of Alzheimer's disease | - | - | are analyzed | #3 |
Lipids constitute almost 60% of the brain's dry weight, and they are thought to be involved in inflammation, neurotransmission and synaptic plasticity. The brain mostly contains sphingolipids, glycerophospholipids and cholesterol which are abundant in myelin and neuronal membranes. The recent rise of the promising area of lipidomic data can be used as a diagnosing tool at the early stages of Alzheimer's disease allowing novel therapeutic targets. In this review, altered lipid metabolites as well as the impact of diet in the progress of Alzheimer's disease (AD) are analyzed.